Literature DB >> 7678298

Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.

J T Stapleton1, V Raina, P L Winokur, K Walters, D Klinzman, E Rosen, J H McLinden.   

Abstract

Hepatitis A virus (HAV) has an immunodominant neutralization antigenic site. By using a panel of monoclonal antibodies targeted against the HAV neutralization antigenic site, it was shown that three epitopes within this site are present on 14S subunits (pentamers of the structural unit). In contrast, two other epitopes within this site are formed upon assembly of 14S subunits into capsids. Thus, the epitopes recognized by these two monoclonal antibodies are formed either by a conformational change in the antigenic site or by the juxtaposition of epitope fragments present on different 14S subunits during assembly of 14S into 70S particles. Both 14S and 70S particles elicited HAV-neutralizing antibodies in mice; thus, these particles may be useful for HAV vaccine development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678298      PMCID: PMC237464     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  Immunoglobulin prophylaxis for hepatitis A.

Authors:  P L Winokur; J T Stapleton
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

2.  Identification of residues in VP2 that contribute to poliovirus neutralization antigenic site 3B.

Authors:  C Reynolds; G Page; H Zhou; M Chow
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

3.  In vitro assembly of poliovirus 14 S subunits: identification of the assembly promoting activity of infected cell extracts.

Authors:  B Rombaut; A Foriers; A Boeyé
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

Review 4.  Recent advances in hepatitis A vaccine development.

Authors:  G Siegl; S M Lemon
Journal:  Virus Res       Date:  1990-10       Impact factor: 3.303

5.  Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers.

Authors:  G Wiedermann; F Ambrosch; H Kollaritsch; H Hofmann; C Kunz; E D'Hondt; A Delem; F E André; A Safary; J Stéphenne
Journal:  Vaccine       Date:  1990-12       Impact factor: 3.641

6.  Specific immunoglobulin M response to hepatitis A virus determined by solid-phase radioimmunoassay.

Authors:  S M Lemon; C D Brown; D S Brooks; T E Simms; W H Bancroft
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

7.  The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles.

Authors:  P L Winokur; J H McLinden; J T Stapleton
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

8.  Hepatitis A virus attachment to cultured cell lines.

Authors:  J T Stapleton; J Frederick; B Meyer
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

9.  Identification and characterization of incomplete hepatitis A virus particles.

Authors:  F Ruchti; G Siegl; M Weitz
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

10.  Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies.

Authors:  L H Ping; S M Lemon
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more
  13 in total

1.  Antigenic hepatitis A virus structures may be produced in Escherichia coli.

Authors:  Glòria Sánchez; Santiago Caballero; Susana Guix; Albert Bosch; Rosa M Pintó
Journal:  Appl Environ Microbiol       Date:  2003-03       Impact factor: 4.792

2.  Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies.

Authors:  M A Riddell; F Li; D A Anderson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Molecular characterization of hepatitis a virus isolates from a transcontinental shellfish-borne outbreak.

Authors:  Glòria Sánchez; Rosa M Pintó; Hermelinda Vanaclocha; Albert Bosch
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 4.  Hepatitis A Virus Genome Organization and Replication Strategy.

Authors:  Kevin L McKnight; Stanley M Lemon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

5.  Hepatitis A virus adaptation to cellular shutoff is driven by dynamic adjustments of codon usage and results in the selection of populations with altered capsids.

Authors:  M Isabel Costafreda; Francisco J Pérez-Rodriguez; Lucía D'Andrea; Susana Guix; Enric Ribes; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

6.  Mimicry of the immunodominant conformation-dependent antigenic site of hepatitis A virus by motifs selected from synthetic peptide libraries.

Authors:  S Mattioli; L Imberti; R Stellini; D Primi
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  Capsid region involved in hepatitis A virus binding to glycophorin A of the erythrocyte membrane.

Authors:  Glòria Sánchez; Lluís Aragonès; M Isabel Costafreda; Enric Ribes; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Molecular basis of the behavior of hepatitis a virus exposed to high hydrostatic pressure.

Authors:  Lucía D'Andrea; Francisco J Pérez-Rodríguez; M Isabel Costafreda; Nerea Beguiristain; Cristina Fuentes; Teresa Aymerich; Susana Guix; Albert Bosch; Rosa M Pintó
Journal:  Appl Environ Microbiol       Date:  2014-08-08       Impact factor: 4.792

9.  Recombinant hepatitis A virus antigen: improved production and utility in diagnostic immunoassays.

Authors:  F D LaBrecque; D R LaBrecque; D Klinzman; S Perlman; J B Cederna; P L Winokur; J Q Han; J T Stapleton
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Hepatitis A virus mutant spectra under the selective pressure of monoclonal antibodies: codon usage constraints limit capsid variability.

Authors:  Lluís Aragonès; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.